Biotechnology Stocks
R&D-intensive firms focused on the development of novel therapeutic modalities, synthetic biology platforms, and biosimilars to address unmet medical needs. Revenue models are characterized by long-term capital consumption, high binary risk surrounding clinical trial milestones, and reliance on intellectual property protection to secure future market exclusivity.
As of Oct 23, 2026, Biotechnology has 831 US-listed companies worth $6.5T combined. The median member moved +1.0% over the past week; GALDY led among the 25 largest at +9.2% and MRNA trailed at -8.2%.
Companies in Biotechnology
- LLY – Eli Lilly and Company, $1.1T
- JNJ – Johnson & Johnson, $645B
- ABBV – AbbVie Inc, $505B
- NVS – Novartis AG ADR, $287B
- AZN – AstraZeneca PLC, $266B
- TMO – Thermo Fisher Scientific Inc, $249B
- AMGN – Amgen Inc, $237B
- GILD – Gilead Sciences Inc, $193B
- NVO – Novo Nordisk A/S, $172B
- PFE – Pfizer Inc, $171B
- DHR – Danaher Corporation, $162B
- VRTX – Vertex Pharmaceuticals Inc, $136B
- BMY – Bristol-Myers Squibb Company, $129B
- GSK – GlaxoSmithKline PLC ADR, $103B
- SNY – Sanofi ADR, $99.7B
- REGN – Regeneron Pharmaceuticals Inc, $82.9B
- MRNA – Moderna Inc, $79.9B
- NTRA – Natera Inc, $57.9B
- ARGX – argenx NV ADR, $54.9B
- GALDY – GALDERMA GROUP AG, $54B
- VEEV – Veeva Systems Inc Class A, $52.2B
- A – Agilent Technologies Inc, $48.8B
- VYLR – Vylor Inc., $47.5B
- TEVA – Teva Pharma Industries Ltd ADR, $46B
- IQV – IQVIA Holdings Inc, $45.8B
- ONC – BeiGene, Ltd., $43B
- ILMN – Illumina Inc, $40.7B
- RVMD – Revolution Medicines Inc, $40.2B
- BIIB – Biogen Inc, $37B
- RPRX – Royalty Pharma Plc, $36.8B
- ZTS – Zoetis Inc, $33.9B
- ALNY – Alnylam Pharmaceuticals Inc, $30B
- WST – West Pharmaceutical Services Inc, $27.7B
- ROIV – Roivant Sciences Ltd, $27.1B
- GMAB – Genmab AS, $26.9B
- LH – Laboratory Corporation of America Holdings, $26.7B
- UTHR – United Therapeutics Corporation, $25.1B
- IFF – International Flavors & Fragrances Inc, $23.9B
- INCY – Incyte Corporation, $23.7B
- BNTX – BioNTech SE, $22.9B
- GH – Guardant Health Inc, $21.9B
- INSM – Insmed Inc, $20.4B
- MEDP – Medpace Holdings Inc, $18.3B
- RVTY – Revvity Inc., $17.7B
- CRL – Charles River Laboratories, $16.6B
- EXEL – Exelixis Inc, $16.2B
- ASND – Ascendis Pharma AS, $16B
- NBIX – Neurocrine Biosciences Inc, $14.6B
- ICLR – ICON PLC, $14.3B
- HALO – Halozyme Therapeutics Inc, $14.1B
- JAZZ – Jazz Pharmaceuticals PLC, $13.9B
- BBIO – BridgeBio Pharma Inc, $13.4B
- DOC – Healthpeak Properties Inc, $13.1B
- SMMT – Summit Therapeutics PLC, $12.3B
- TEM – Tempus AI, Inc. Class A Common Stock, $12.3B
- AVTR – Avantor Inc, $11.7B
- CORT – Corcept Therapeutics Incorporated, $11.6B
- TECH – Bio-Techne Corp, $11.4B
- RGEN – Repligen Corporation, $11.3B
- RDY – Dr. Reddy’s Laboratories Ltd ADR, $11B
- BMRN – Biomarin Pharmaceutical Inc, $10.8B
- GKOS – Glaukos Corp, $10.4B
- QGEN – Qiagen NV, $10.4B
- MDGL – Madrigal Pharmaceuticals Inc, $10B
- PCVX – Vaxcyte Inc, $9.9B
- TWST – Twist Bioscience Corp, $9.9B
- TXG – 10X Genomics Inc, $9.8B
- BIO – Bio-Rad Laboratories Inc, $9.6B
- KRYS – Krystal Biotech Inc, $9.6B
- KYMR – Kymera Therapeutics Inc, $9.3B
- PTGX – Protagonist Therapeutics Inc, $9B
- CAI – Caris Life Sciences, Inc. Common Stock, $9B
- IBRX – Immunitybio Inc, $8.8B
- SYRE – Spyre Therapeutics Inc., $8.7B
- CYTK – Cytokinetics Inc, $8.5B
- CTVA – Corteva Inc, $8.5B
- ARWR – Arrowhead Pharmaceuticals Inc, $8.2B
- TGTX – TG Therapeutics Inc, $8.1B
- ABVX – Abivax SA American Depositary Shares, $7.7B
- SHMXY – Shimadzu Corp, $7.6B
- AXSM – Axsome Therapeutics Inc, $7.6B
- ALKS – Alkermes Plc, $7.4B
- ARE – Alexandria Real Estate Equities Inc, $7.4B
- IONS – Ionis Pharmaceuticals Inc, $7.3B
- PRAX – Praxis Precision Medicines Inc, $7.2B
- AMRX – Amneal Pharmaceuticals, Inc. Class A Common Stock, $7.1B
- LNTH – Lantheus Holdings Inc, $6.5B
- IOVA – Iovance Biotherapeutics Inc, $6.4B
- KNSA – Kiniksa Pharmaceuticals Ltd, $6.3B
- RYTM – Rhythm Pharmaceuticals Inc, $6.3B
- LGND – Ligand Pharmaceuticals Incorporated, $6.1B
- IMVT – Immunovant Inc, $5.9B
- MANE – Veradermics, Incorporated, $5.8B
- BLTE – Belite Bio Inc ADR, $5.8B
- GRAL – GRAIL, LLC, $5.7B
- STVN – Stevanato Group SpA, $5.5B
- COGT – Cogent Biosciences Inc, $5.5B
- KOD – Kodiak Sciences Inc, $5.4B
- MIRM – Mirum Pharmaceuticals Inc, $5.3B
- CGON – CG Oncology, Inc. Common stock, $5.3B
- PTCT – PTC Therapeutics Inc, $5.3B
- ORKA – Oruka Therapeutics, Inc., $5.2B
- GRFS – Grifols SA ADR, $5.2B
- SRRK – Scholar Rock Holding Corp, $5.1B
- ERAS – Erasca Inc, $5.1B
- TVTX – Travere Therapeutics Inc, $4.9B
- BLLN – BillionToOne, Inc. Class A Common Stock, $4.8B
- CRSP – Crispr Therapeutics AG, $4.8B
- RGC – Regencell Bioscience Holdings Ltd, $4.8B
- TNGX – Tango Therapeutics Inc, $4.5B
- DFTX – Definium Therapeutics, Inc., $4.4B
- EWTX – Edgewise Therapeutics Inc, $4.3B
- DNTH – Dianthus Therapeutics Inc., $4.3B
- ARQT – Arcutis Biotherapeutics Inc, $4B
- RLAY – Relay Therapeutics Inc, $4B
- ADPT – Adaptive Biotechnologies Corp, $3.9B
- ABCL – Abcellera Biologics Inc, $3.8B
- TLX – Telix Pharmaceuticals Limited, $3.8B
- VCYT – Veracyte Inc, $3.7B
- LEGN – Legend Biotech Corp, $3.7B
- AMLX – Amylyx Pharmaceuticals Inc, $3.6B
- OGN – Organon & Co, $3.6B
- CDNA – CareDx Inc, $3.6B
- LQDA – Liquidia Technologies Inc, $3.6B
- XENE – Xenon Pharmaceuticals Inc, $3.5B
- ACAD – ACADIA Pharmaceuticals Inc, $3.5B
- IDYA – Ideaya Biosciences Inc, $3.5B
- TARS – Tarsus Pharmaceuticals Inc, $3.3B
- VKTX – Viking Therapeutics Inc, $3.3B
- CELC – Celcuity LLC, $3.2B
- PBLS – Parabilis Medicines, Inc. Common Stock, $3.1B
- HTGC – Hercules Capital, Inc., $3.1B
- IRON – Disc Medicine Inc., $3B
- DNLI – Denali Therapeutics Inc, $3B
- DYN – Dyne Therapeutics Inc, $2.9B
- ELVN – Enliven Therapeutics Inc., $2.9B
- NRIX – Nurix Therapeutics Inc, $2.9B
- RCUS – Arcus Biosciences Inc, $2.8B
- ZLAB – Zai Lab Ltd, $2.7B
- NEOG – Neogen Corporation, $2.6B
- VRDN – Viridian Therapeutics Inc, $2.5B
- BEAM – Beam Therapeutics Inc, $2.5B
- MBX – MBX Biosciences, Inc. Common Stock, $2.5B
- HCM – HUTCHMED DRC, $2.5B
- SUPN – Supernus Pharmaceuticals Inc, $2.4B
- MRVI – Maravai Lifesciences Holdings Inc, $2.4B
- NAMS – NewAmsterdam Pharma Company N.V. Ordinary Shares, $2.4B
- CLDX – Celldex Therapeutics Inc, $2.3B
- SLS – Sellas Life Sciences Group Inc, $2.3B
- PGEN – Precigen Inc, $2.3B
- VERA – Vera Therapeutics Inc, $2.2B
- AGIO – Agios Pharm, $2.2B
- AUPH – Aurinia Pharmaceuticals Inc, $2.2B
- AXGN – Axogen Inc, $2.2B
- FTRE – Fortrea Holdings Inc., $2.1B
- NEO – NeoGenomics Inc, $2.1B
- HRMY – Harmony Biosciences Holdings, $2.1B
- VCEL – Vericel Corp Ord, $2.1B
- PHVS – Pharvaris BV, $2.1B
- IMNM – Immunome Inc, $2.1B
- WGS – GeneDx Holdings Corp., $2B
- XERS – Xeris Pharmaceuticals Inc, $2B
- BCRX – BioCryst Pharmaceuticals Inc, $2B
- ALMR – Alamar Biosciences, Inc. Common Stock, $2B
- ZYME – Zymeworks Inc. Common Stock, $1.9B
- RXRX – Recursion Pharmaceuticals Inc, $1.9B
- MLYS – Mineralys Therapeutics, Inc. Common Stock, $1.9B
- BRVE – Braveheart Bio, Inc. Common Stock, $1.9B
- BLFS – BioLife Solutions Inc, $1.9B
- ALVO – Alvotech, $1.9B
- NVAX – Novavax Inc, $1.9B
- XNCR – Xencor Inc, $1.9B
- GENB – Generate Biomedicines, Inc. Common Stock, $1.8B
- SEPN – Septerna, Inc. Common Stock, $1.8B
- ZBIO – Zenas BioPharma, Inc. Common Stock, $1.8B
- TRVI – Trevi Therapeutics Inc, $1.8B
- VIR – Vir Biotechnology Inc, $1.8B
- SRPT – Sarepta Therapeutics Inc, $1.8B
- BHVN – Biohaven Ltd., $1.8B
- NVCR – Novocure Ltd, $1.8B
- PVLA – Palvella Therapeutics, Inc, $1.7B
- SDGR – Schrodinger Inc, $1.7B
- MESO – Mesoblast Ltd, $1.7B
- NUVB – Nuvation Bio Inc, $1.7B
- KLRA – Kailera Therapeutics, Inc. Common Stock, $1.7B
- PSNL – Personalis Inc, $1.7B
- URGN – UroGen Pharma Ltd, $1.7B
- COAG – Hemab Therapeutics Holdings, Inc. Common Stock, $1.7B
- NBTX – Nanobiotix, $1.7B
- OCUL – Ocular Therapeutix Inc, $1.7B
- STOK – Stoke Therapeutics Inc, $1.7B
- GPCR – Structure Therapeutics Inc. American Depositary Shares, $1.6B
- NTLA – Intellia Therapeutics Inc, $1.6B
- QURE – Uniqure NV, $1.6B
- CMPS – Compass Pathways Plc, $1.6B
- RARE – Ultragenyx, $1.6B
- KRSA – Korsana Biosciences, Inc., $1.5B
- ANAB – AnaptysBio Inc, $1.5B
- IMCR – Immunocore Holdings Ltd, $1.5B
- MAZE – Maze Therapeutics, Inc. Common Stock, $1.5B
Showing the 200 largest of 831 members by market cap.